Last updated 2026-07-26
TL;DR
CJC-1295 and sermorelin are both GHRH analogues, but CJC-1295's modified backbone (and optional DAC) gives it a half-life measured in hours to days, versus sermorelin's roughly 10-20 minutes. That difference drives dosing frequency and cost, not necessarily better outcomes; neither has FDA-approved bodybuilding or anti-aging indications, and long-term human data is thin for both.
What is the core difference between CJC-1295 and sermorelin?
Both are synthetic analogues of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that tells the pituitary to release growth hormone. The core difference is durability. Sermorelin is essentially GHRH(1-29), the shortest fragment that retains full biological activity, and it behaves close to native GHRH: fast onset, fast clearance, half-life around 10 to 20 minutes [1]. CJC-1295 is a longer, chemically modified analogue (tetrasubstituted GHRH(1-29) with four amino acid substitutions) designed to resist enzymatic breakdown, and it optionally carries a Drug Affinity Complex (DAC) that binds serum albumin and stretches its half-life out to roughly 6 to 8 days [2]. So one is a short-acting mimic of the body's own signal. The other is an engineered version built specifically to hang around longer. That's the whole story mechanically. Everything else, dosing schedule, cost, injection frequency, flows from that half-life gap. Neither peptide is FDA-approved for anything sold online today. Sermorelin did have a branded, FDA-approved product (Geref) for diagnostic and pediatric growth hormone deficiency testing, but that product was discontinued by the manufacturer years ago [3]. CJC-1295 has never had FDA approval for any indication; what exists is a body of preclinical and early-phase human pharmacology data, most of it from the mid-2000s [2].
How does the half-life difference actually change what you'd feel or do?
Half-life determines injection frequency and how GH release is shaped over the day, not necessarily the total GH output. Sermorelin's short half-life means it needs dosing once daily, usually at night before sleep, timed to amplify the body's natural nocturnal GH pulse. Because it clears fast, it mimics a single physiologic GHRH pulse reasonably well. This is part of why the old FDA-approved Geref product was dosed as a once-daily subcutaneous injection for pediatric growth hormone deficiency workups [3]. CJC-1295 without DAC (sometimes labeled CJC-1295 "no-DAC" or, confusingly in gray-market circles, mod GRF 1-29) has a half-life closer to 30 minutes, similar in spirit to sermorelin but somewhat more resistant to degradation. CJC-1295 with DAC is the outlier: its albumin-binding tail gives it that multi-day half-life, which is why some protocols use it just once or twice a week instead of daily [2]. The tradeoff is that a multi-day-acting GHRH analogue produces sustained, elevated GHRH signaling rather than a pulse, and pulsatile GH release is generally considered closer to normal physiology than constant elevation. Whether that distinction actually changes body composition or safety outcomes in humans has not been well studied outside small early trials.
CJC-1295 vs sermorelin: side-by-side comparison
| Attribute | Sermorelin | CJC-1295 (no DAC) | CJC-1295 (with DAC) | |||||
|---|---|---|---|---|---|---|---|---|
| Structure | GHRH(1-29), native fragment | Modified GHRH(1-29), 4 amino acid substitutions | Same modified backbone + DAC (albumin-binding) | |||||
| Approx. half-life | ~10-20 minutes [1] | ~30 minutes [2] | ~6-8 days [2] | |||||
| Typical injection frequency (research protocols) | Once daily | Once or twice daily | Once every 3-7 days | |||||
| FDA-approved product ever existed? | Yes, Geref, discontinued [3] | No | No | GH release pattern | Mimics single physiologic pulse | Mimics pulse, slightly extended | Sustained elevation, less pulsatile | |
| Typical pairing | Occasionally with GHRP | Very commonly with ipamorelin | Very commonly with ipamorelin | |||||
| Cost driver | Cheaper peptide, more vials/month for daily use | Moderate | Higher per-vial cost but fewer doses needed | For exact milligram ranges and reconstitution math on the CJC-1295 side, see the CJC-1295 dosage guide and the CJC-1295 DAC dosage calculator. |
Is CJC-1295 stronger than sermorelin, or just longer-acting?
Longer-acting is the accurate way to describe it. "Stronger" implies a bigger GH pulse or more downstream IGF-1 rise, and the honest answer is that head-to-head human trials comparing CJC-1295 directly against sermorelin for GH or IGF-1 output essentially don't exist in the peer-reviewed literature. What we do have: a 2006 study in the Journal of Clinical Endocrinology & Metabolism testing CJC-1295 (with DAC) in healthy adults found that a single injection raised mean GH levels for 6 days and, with multiple doses over 2 to 3 months, produced sustained increases in IGF-1 (a common proxy marker for GH activity), with the study's authors reporting IGF-1 levels remained elevated by 1.5 to 3-fold above baseline throughout dosing [2]. That's the most cited human trial for CJC-1295, and it used the DAC form specifically. Sermorelin's human data is older, mostly from the 1980s-90s diagnostic and pediatric GHD literature, and wasn't designed to answer the same performance-oriented questions people ask on forums today [4]. So: CJC-1295 with DAC clearly produces a more sustained IGF-1 elevation than a single sermorelin dose would, simply because it's still in circulation days later. That's a duration effect, not proof of a larger physiologic ceiling. Nobody has run the trial that would settle "which one produces more total GH release over a month at matched doses," and until someone does, claims of one being categorically more potent are extrapolation.
Why is CJC-1295 usually paired with ipamorelin, and does sermorelin get paired too?
Both peptides are GHRH analogues, meaning they act on the GHRH receptor. Ipamorelin is a different class entirely: a ghrelin receptor agonist (a GH secretagogue, sometimes called a GHRP) that stimulates GH release through a separate pathway and also suppresses somatostatin, the hormone that normally puts the brakes on GH release [5]. The rationale for combining a GHRH analogue with a ghrelin-receptor agonist is pharmacologic complementarity. Two different receptors converging on the same downstream output (pituitary GH release) can produce a larger combined pulse than either alone, a pattern shown in older combined GHRH/GHRP research [6]. This is real receptor biology, not forum invention. What is not settled is whether that combined pulse translates into meaningfully better body composition, sleep, or recovery outcomes in otherwise healthy adults over months of use; the supporting studies are mostly short-term GH/IGF-1 measurement studies, not long-term outcome trials. Sermorelin can technically be paired with ipamorelin too, and some clinics do run that combination, banking on the same GHRH-plus-ghrelin-receptor logic. But CJC-1295 (particularly the DAC version) dominates the pairing conversation online mostly because its longer action window fits neater into twice-weekly protocols, while sermorelin's short half-life means daily dosing is basically mandatory regardless of what it's paired with. For the mechanism detail on CJC-1295 alone, see CJC-1295.
What does the evidence actually say, versus what's forum lore?
This is worth being blunt about, because a lot of what circulates about CJC-1295 and sermorelin online did not originate in a lab. What's actually studied: CJC-1295's pharmacokinetics and its GH/IGF-1 effects in a small number of healthy adult trials from the mid-2000s [2]. Sermorelin's GH-stimulating effect in pediatric growth hormone deficiency diagnostic testing, and its historical FDA-approved use for that narrow purpose before Geref was discontinued [3]. GHRH plus ghrelin-agonist combined effects on GH release, studied mechanistically in endocrinology research going back decades [6]. What's forum lore, not evidence: claims that CJC-1295/ipamorelin stacks meaningfully reverse aging, produce dramatic fat loss independent of diet, or are safer than prescription GH because they're "natural" peptides. None of that has trial support. The muscle-forum ecosystem also frequently conflates "CJC-1295" with "mod GRF 1-29" and uses inconsistent dosing units (mcg vs mg, daily vs weekly) that don't match the pharmacology of the DAC and no-DAC forms, which causes real dosing confusion for buyers. If you're trying to sort a specific number claim you saw on a forum, cross-check it against the CJC-1295 dosage page before assuming it's accurate.
How do side effects compare between CJC-1295 and sermorelin?
Reported side effect profiles overlap heavily because both work through the same downstream mechanism (GH release), and most of what's reported is injection-site reaction and short-term flushing. In the 2006 CJC-1295 human trial, reported adverse events included injection site reactions (pain, redness, itching) and were generally described as mild to moderate; the study did not report serious adverse events at the doses tested [2]. Sermorelin's older diagnostic-use safety data similarly lists injection site reactions, flushing, and occasional headache as the main complaints [3][4]. The theoretical concern that gets raised more with CJC-1295 (DAC) specifically is that sustained, non-pulsatile GH/IGF-1 elevation over weeks could carry different long-term risk than the brief pulses sermorelin produces, since chronically elevated IGF-1 is a marker researchers watch for in unrelated contexts (some observational cancer epidemiology literature has flagged higher IGF-1 as associated with certain cancer risks, though causality in this context is unproven and that literature isn't about peptide therapy specifically). No trial of CJC-1295 has run long enough or with enough participants to answer that question directly. For the fuller adverse-event rundown and what's documented versus speculative, see CJC-1295 side effects.
Which one is cheaper, CJC-1295 or sermorelin?
Per vial, sermorelin is usually the cheaper peptide to manufacture and buy, largely because it's a shorter, simpler synthesis. But per-vial price isn't the number that matters. What matters is monthly cost, and that depends on dosing frequency. Since sermorelin needs daily injections and CJC-1295 with DAC only needs dosing every 3 to 7 days, a cheaper-per-vial sermorelin protocol can end up costing a similar amount monthly to a pricier-per-vial CJC-1295/DAC protocol, because you're buying and reconstituting more vials of it. No-DAC CJC-1295 sits in between: daily-to-twice-daily dosing like sermorelin, but usually priced closer to the modified-peptide tier. Pricing varies a lot by provider, purity testing, and whether it's sold as a standalone peptide or pre-blended with ipamorelin. If you're comparing actual current listings, check CJC-1295 for sale rather than relying on a fixed number here, since peptide pricing shifts with supply and isn't something a static article can quote reliably.
Does the DAC vs no-DAC distinction matter for choosing between CJC-1295 and sermorelin?
Yes, and it's a distinction a lot of buyers miss entirely. "CJC-1295" isn't one product; it's a peptide backbone that exists in two versions with genuinely different pharmacokinetics. CJC-1295 without DAC has a half-life around 30 minutes, similar in duration category to sermorelin, and needs frequent dosing to maintain any sustained effect. CJC-1295 with DAC has the multi-day half-life that lets it be dosed weekly or twice weekly [2]. If someone is comparing sermorelin to "CJC-1295" without specifying which version, they're not making an apples-to-apples comparison, because no-DAC CJC-1295 behaves pharmacokinetically much closer to sermorelin than to its own DAC-bearing sibling. This matters practically. A protocol built around twice-weekly injections (DAC) and a protocol built around nightly injections (no-DAC or sermorelin) are different commitments in terms of adherence, storage, and reconstitution frequency. Get the DAC detail straight before comparing costs or effects; see CJC-1295 with DAC for the full pharmacokinetic breakdown.
Which is better for beginners, sermorelin or CJC-1295?
There's no clinical consensus ranking one as "better," but the practical tradeoffs differ enough to matter for a first-time user. Sermorelin's short half-life means if something feels off, it clears your system in under an hour; there's less of a "stuck with it for days" scenario. That's a meaningful safety-adjacent convenience for someone unsure how they'll react. No-DAC CJC-1295 shares that fast-clearance property. CJC-1295 with DAC, by contrast, means any side effect or reaction sticks around for the multi-day window the drug is active, which is a real consideration for a first-timer who hasn't gauged their own response yet. On the other hand, DAC's weekly-or-twice-weekly schedule is easier to stay consistent with than a nightly injection habit, and adherence matters a lot in any self-administered protocol. Neither peptide is regulated or dosed under FDA-approved labeling for the uses most people are buying them for, so "beginner-friendly" here is really about logistics and reversibility, not about one being medically safer in an approved-use sense.
What's the actual regulatory and legal status of these peptides?
Neither CJC-1295 nor sermorelin (in its currently sold forms) is FDA-approved for sale as a prescription drug in the US today. Sermorelin's one FDA-approved branded product, Geref, was discontinued by its manufacturer [3]. CJC-1295 has never carried FDA approval; it exists in the marketplace mainly as a research-use product sold by peptide vendors, which is a distinct regulatory category from an approved drug and generally not marketed for human self-administration. The FDA maintains a list of bulk drug substances that can be nominated for use in compounding, and substances have to meet specific evaluation criteria, including safety and a demonstrated clinical need, before they qualify . GH-secretagogue peptides including several used off-label have drawn agency attention for not meeting those criteria consistently. Buyers should understand that "research use only" labeling on a peptide vial is a real legal distinction, not marketing language, and it changes what claims a seller can legally make and what oversight the product has had.
Frequently asked questions
Is CJC-1295 the same thing as sermorelin?
No. Both are GHRH analogues, but CJC-1295 is a chemically modified, longer-lasting molecule, while sermorelin is close to the native GHRH(1-29) fragment with a short half-life of about 10-20 minutes. They act on the same receptor but behave very differently in the body over time [1][2].
Can I switch from sermorelin to CJC-1295 without adjusting my routine?
No, the dosing schedule has to change. Sermorelin typically requires nightly injection because it clears in under 30 minutes. CJC-1295 with DAC is dosed once every few days to weekly because of its multi-day half-life; no-DAC CJC-1295 needs more frequent dosing similar to sermorelin [2].
Does CJC-1295 or sermorelin raise IGF-1 more?
The one human trial most often cited (CJC-1295 with DAC, 2006) reported sustained IGF-1 elevations of roughly 1.5 to 3-fold above baseline over 2-3 months of dosing [2]. No direct head-to-head trial against sermorelin exists, so a rank-order claim of which raises IGF-1 more isn't supported by current published research.
Why is CJC-1295 usually stacked with ipamorelin instead of sermorelin?
It's not that sermorelin can't be paired with ipamorelin, it's that CJC-1295's longer duration fits more naturally into a twice-weekly protocol alongside ipamorelin's own frequent dosing, and the GHRH-plus-ghrelin-receptor-agonist combination is grounded in real receptor research even though long-term outcome data in healthy adults is limited [5][6].
Which has fewer side effects, CJC-1295 or sermorelin?
Reported side effects overlap: injection site reactions, flushing, occasional headache, generally mild in both cases based on available trial and clinical data [2][3][4]. The theoretical difference is that CJC-1295 with DAC sustains elevated GH/IGF-1 signaling for days, an exposure pattern that hasn't been studied long-term for safety.
Is sermorelin still FDA-approved?
Sermorelin's branded FDA-approved product, Geref, was discontinued by its manufacturer and is no longer marketed [3]. Sermorelin sold today through compounding pharmacies or peptide vendors is not under that original approval, and buyers should understand the regulatory distinction between an approved drug and a compounded or research-use product.
Is CJC-1295 with DAC or without DAC better?
Neither is universally "better", they serve different dosing preferences. DAC gives a 6-8 day half-life for infrequent dosing [2]; no-DAC gives roughly 30-minute clearance for more frequent dosing and, arguably, a GH release pattern closer to a natural pulse. The choice depends on adherence preference and risk tolerance for sustained exposure.
How much does CJC-1295 cost compared to sermorelin per month?
Sermorelin is usually cheaper per vial, but needs daily dosing, while CJC-1295 with DAC costs more per vial but needs only weekly to twice-weekly dosing. Total monthly costs can end up similar; check current vendor pricing directly since peptide costs shift with supply and purity testing standards.
Do CJC-1295 and sermorelin work for weight loss?
Neither is FDA-approved for weight loss. Their studied effect is raising GH/IGF-1 levels, and elevated GH does have some documented lipolytic (fat-mobilizing) activity in endocrinology literature, but no trial of either peptide has established weight loss as a primary approved outcome in healthy adults.
Can women use CJC-1295 or sermorelin the same way as men?
Published human trials for both peptides have generally been small and haven't consistently separated outcomes or dosing recommendations by sex in a way that gives a clear, sourced answer here. Anyone considering either should discuss individual health history with a qualified prescriber rather than relying on generic dosing found online.
What does 'no-DAC' mean on a CJC-1295 label?
It means the peptide does not have the Drug Affinity Complex (DAC) attached, the modification that binds to albumin in blood and extends half-life to days. No-DAC CJC-1295 clears in roughly 30 minutes, closer in duration to sermorelin, and needs more frequent dosing to sustain any effect [2].
Is there a study directly comparing CJC-1295 to sermorelin?
Not in the peer-reviewed literature currently available. The main CJC-1295 human trial (2006, Journal of Clinical Endocrinology & Metabolism) and sermorelin's older diagnostic-use studies were conducted separately, for different purposes, using different endpoints, so a rigorous head-to-head comparison doesn't exist yet [2][4].
Sources
- Journal of Clinical Endocrinology & Metabolism, Teichman et al. 2006, 'Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295': CJC-1295 with DAC half-life of approximately 6-8 days and sustained IGF-1 elevation of 1.5-3 fold over 2-3 months
- U.S. FDA, Drugs@FDA database entry for Geref (sermorelin acetate): Geref was an FDA-approved sermorelin product later discontinued
- National Institutes of Health, PubMed, PMID 2153081, sermorelin diagnostic use in growth hormone deficiency testing: Sermorelin historical use and safety profile in pediatric GH deficiency diagnostic testing
- Endocrine Reviews, Endocrine Society, clinical review on ghrelin and GH secretagogues: Ghrelin receptor agonists like ipamorelin act through a separate GH-release pathway and suppress somatostatin
- National Institutes of Health, PubMed, PMID 2842301, GHRH and GHRP combined effect on GH release: Combined GHRH and GHRP administration produces a larger GH release than either alone
- U.S. FDA, Federal Register notice, Bulk Drug Substances for Compounding Under Section 503A, evaluation criteria: FDA criteria bulk substances including GH-secretagogue peptides must meet for compounding